###### Strengths and limitations of this study

-   Independent, duplicate screening and extraction were conducted to minimise bias.

-   It is possible that some priority-setting exercises were not identified despite the use of a broad search strategy.

-   All priority-setting exercises were conducted in high-income countries, and thus, their results may not be generalisable to middle-income or low-income settings.

Background {#s1}
==========

Conditions, such as low back and neck pain, osteoarthritis, osteoporosis, rheumatoid arthritis, gout and 'other' musculoskeletal (MSK) conditions, have the fourth greatest impact on global health according to the Global Burden of Disease study.[@R1] In Australia, MSK conditions account for over 10% of the total disease burden and make up almost a quarter (23%) of the total non-fatal burden.[@R2] They are among the top 30 most frequently managed chronic conditions in Australia,[@R3] and contribute notably to total health expenditure.[@R4] In 2012, the total cost of arthritis and other MSK conditions in Australia was an estimated \$5.5 billion, including both direct (treatment), and indirect (loss of productivity), costs.[@R4]

A review of MSK trial funding by the Australian National Health and Medical Research Council (NHMRC) between 2009 and 2013 identified that funding for this area was disproportionately low relative to its burden despite it being an acknowledged National Health Priority Area.[@R5] It is therefore imperative that the limited funding directed to MSK health focus on the most important research priorities in the field to ensure the highest health return on investment.[@R6]

There are many ways of approaching priority setting including using Delphi methods (iterative consultations with stakeholders), trend analysis and modelling (to predict future burdens), scenario discussion, matrix approaches (using quantifiable data to consider the potential effect), and discrete choice methods (to evaluate trade-offs).[@R7] The James Lind Alliance, for example, advocates a mixture of literature reviews, Delphi surveys and workshops that involve a range of stakeholders in identifying and ranking the top 10 priorities in order of importance.[@R9]

The Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network was recently established to optimise MSK health through high quality, collaborative clinical trials research and to build research capacity in this field.[@R10] To ensure that we focus on the most important evidence and evidence-practice gaps that are of most relevance to patients, clinicians, consumers and policy-makers, we aim to establish our own list of research priorities. To inform this work, we performed a scoping review of previous priority-setting projects for MSK conditions. Our aims were both to describe the methods used to establish research priorities, as well as to synthesise the priorities that have been identified previously. In particular, we were interested in whether or not any previous priority-setting projects had used a transparent method to order their set of priorities and whether any identified priorities would be of use in our own priority-setting process.

Methods {#s2}
=======

Selection criteria {#s2a}
------------------

We included articles that reported on research prioritisation for any type of MSK condition. We defined MSK conditions as any form of arthritis (eg, rheumatoid arthritis, osteoarthritis, gout), autoimmune rheumatic conditions (eg, systemic lupus erythematosus, SLE), regional specific or non-specific MSK conditions (eg, low back pain), fractures and osteoporosis. Articles were included if they directly identified research priorities or research gaps from stakeholders including clinicians, consumers and researchers, irrespective of whether they were highly refined research questions or broad/more general research topics. There was no limitation on age or setting. Priority setting for pain in general or major trauma was excluded. We also excluded editorials, commentaries, narrative reviews, priorities considered as part of clinical guidelines and priorities relating solely to outcome measurement, for example, outcome measures in rheumatology initiatives.

Search strategy {#s2b}
---------------

We searched Ovid MEDLINE and EMBASE since inception to 20 November 2017 unrestricted by language. The specific search terms are listed in online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}. We also searched the reference lists of included articles to identify additional relevant studies, the websites of the James Lind Alliance (<http://www.jla.nihr.ac.uk/>), their priority-setting partnerships (<http://www.jla.nihr.ac.uk/priority-setting-partnerships/>) and their priorities list (<http://www.jla.nihr.ac.uk/top-10-priorities/>), the website of the Cochrane Priority Setting Methods Group (<http://methods.cochrane.org/prioritysetting/resources>), and the Cochrane Musculoskeletal and Cochrane Back groups priority lists for reviews.
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Data abstraction and synthesis {#s2c}
------------------------------

The title and abstracts of identified articles were independently screened by random and different pairs of reviewers across the author group. The full texts of potentially eligible articles were obtained and also screened by random and different pairs of reviewers across the author group. We attempted to contact the authors of any articles that we could not obtain by other means. Discordant decisions were resolved by discussion or a third reviewer (RVJ or RB), if necessary.

For all included articles, two independent reviewers (AMB or SC and another reviewer across the author group) extracted relevant data to a standard data extraction form (online [supplementary appendix 2](#SP2){ref-type="supplementary-material"}). It included the following information: setting, participants (clinicians, consumers, researchers, policy-makers, industry representatives, etc), MSK condition(s), method(s) used to develop research priorities), criteria for priorities (if used), method of priority weighting (if used), funding and the priority topics identified. Differences in data extraction between reviewers were resolved by discussion or by a third reviewer if necessary (RB or RVJ).
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Priorities that were only research topics (eg, 'rehabilitation strategies'),[@R11] were classified as broad priorities, while those that were specific research questions (eg, 'what is the relevance and use of red flags in the management of MSK conditions?'),[@R12] were classified as specific priorities. Two independent reviewers (AMB and either RB, CM or JL) further categorised all identified research priorities into themes. These empirically derived themes were then condensed in number to 13 themes: epidemiology and burden; aetiology and risk factors; screening, diagnosis and assessment; natural history, prognosis and outcome; prevention; treatment (including prediction of response and mechanisms/rationale for treatment); outcome measurement; economic evaluation; implementation; health services and systems; research capacity building; research methods; and patient/consumer perspectives (focus on the impact or well-being of the patient). They were also mapped to a specific condition if relevant. Discrepancies in categorisation were discussed and resolved by consensus. No formal assessment of the quality of the prioritisation exercises was performed.

Patient involvement {#s2d}
-------------------

One consumer representative but no patients were involved in the development, conduct or analysis of this review.

Results {#s3}
=======

Search results {#s3a}
--------------

We retrieved 4185 non-duplicate citations from our searches including 20 from other sources ([figure 1](#F1){ref-type="fig"}). Of these, 4044 citations were excluded after screening titles and abstracts. Of 141 potentially eligible articles, two could not be located in full text (despite attempts to contact the first author) and therefore could not be screened ('awaiting assessment'),[@R13] leaving 139 for full-text review. Of these, 90 were excluded. Reasons for exclusion are summarised in [figure 1](#F1){ref-type="fig"} and detailed in online [supplementary appendix 3](#SP3){ref-type="supplementary-material"}). These included non-research articles, guidelines and articles that did not specify a list of research priorities.
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![Article extraction flow chart.](bmjopen-2018-023962f01){#F1}

Included studies {#s3b}
----------------

### Conditions {#s3b1}

Forty-nine articles fulfilled our inclusion criteria.[@R11] Most articles (n=29, 59%) were published in the last 10 years.[@R11] Twenty-two (45%) made priority recommendations for MSK conditions broadly or recommendations across a range of conditions.[@R12] For single conditions, research priorities for osteoarthritis were identified most often (n=7),[@R11] followed by rheumatoid arthritis (n=4),[@R38] osteoporosis (n=4)[@R37] and back pain (n=4).[@R45] Two studies identified priorities for orthopaedic surgery[@R52] and foot and ankle conditions not otherwise classified by a disease.[@R47] Single studies identified priorities for gout,[@R50] systemic sclerosis,[@R51] surgery for common shoulder conditions[@R49] and juvenile-onset SLE.[@R54]

### Location and approach {#s3b2}

The characteristics of the priority-setting processes in the included articles are summarised in [table 1](#T1){ref-type="table"}. One-third (n=14, 29%) included stakeholders from multiple continents while 33 (67%) were country specific. Almost half (n=23, 47%) used a combination of methods, including literature review, surveys and/or workshops.[@R16] A combination of survey(s) and workshop(s) was the most common multimodal approach, while surveys or focus groups were common in unimodal approaches. Of the 11 (22%), priority-setting exercises that were informed by a systematic review,[@R16] only one explicitly reported their search terms.[@R36]

###### 

Methods, specific characteristics of the priority-setting approach, participants and funding of the included studies (n=49)

                                                                     N (%)
  ------------------------------------------------------------------ -----------------------
  Method/s used to identify priorities                               
    Combination of methods\*                                         23 (46.9)
    Consensus (only)†                                                22 (44.9)
    Survey (only)                                                    4 (8.2)
  Specific characteristics of the priority-setting approach          
    Predefined explicit criteria for what constitutes a priority     2 (4.1)
    Priorities limited to a specific area                            15 (30.6)
    Priorities pregenerated (not produced by stakeholders)           5 (10.2)
    Methods for refining research priorities reported                32 (65.3)
    Ranking of some or all priorities                                34 (69.4)
    Weighting by an explicit method                                  2 (4.1)
    Update or reassessment of an earlier priority-setting activity   5 (10.2)
    Explicit strategy to implement priorities reported               11 (22.4)
  Participants                                                       
    Participants from ≥2 continents                                  14 (28.6)
    UK                                                               12 (24.5)
    USA and/or Canada                                                19 (38.8)
    Europe                                                           2 (4.1)
    Australia                                                        2 (4.1)
    Total no of participants reported (range 9--1396)                35 (71.4)
    Method for identifying participants reported                     23 (46.9)
    Level of stakeholder involvement clear                           28 (57.1)
    Clinicians (only)                                                42 (85.7)/(16 (32.7))
    Consumers or patients (only)                                     19 (38.8)/(6 (12.2))
    Range of stakeholders‡                                           26 (53.1)
    Participants unclear                                             1 (2)
  Funding                                                            
    Not explicitly reported                                          18 (36.7)
    Multiple funders                                                 7 (14.3)
    Professional association§                                        8 (16.3)
    Hospital/institute                                               3 (6.1)
    Government                                                       8 (16.3)
    Consumer organisation                                            2 (4.1)
    Industry                                                         1 (2)
    Not funded                                                       2 (4.1)

\*Studies included multiple methods (eg, survey and workshop).

†Consensus methods could have included workshops, group discussion, expert panels, nominal group techniques, focus groups, Delphi studies.

‡Other stakeholders included government, industry, researchers, educators, managers, administrators and funding agencies.

§Professional associations included orthopaedic nurses and trauma, rheumatology, physiotherapy and chiropractic groups.

### Priority criteria, synthesis, implementation and evaluation {#s3b3}

Only 2 priority-setting exercises (4%) reported explicit criteria for what could be considered a priority,[@R15] 15 (31%) limited priorities to specific research areas (eg, non-pharmacological interventions)[@R17] and 5 (10%) asked participants to rank preidentified priorities (although allowed them to suggest additional items).[@R27] The majority of articles broadly described how identified priorities were refined (n=32, 65%),[@R12] 12 of which (24%) included a thematic analysis.[@R12] While most priority-setting exercises resulted in a ranked list of priorities, only two articles described priority weighting (by giving participants' top three preferences across all categories double weighting,[@R44] or by allocating 100 points across their choices).[@R59] Only four groups or organisations updated or repeated their priority-setting exercise (The National Association of Orthopaedic Nurses,[@R26] The Chartered Society of Physiotherapy[@R14] The International Forum for Primary Care Research on Low Back Pain)[@R46] and the Research Council of the American Orthopaedic Foot and Ankle Society.[@R47] Another group assessed the progress related to chiropractic research priorities but did not generate new priorities.[@R62] Eleven studies (22%) outlined a strategy for implementing their priorities,[@R22] (most of which were published since 2011)[@R22] and one group (5%) reported that they had commenced a clinical trial to investigate one of the priorities identified.[@R43]

### Participants {#s3b4}

Sixteen priority-setting studies only included clinicians,[@R11] six only included consumers or patients[@R18] and in one the participants involved were unclear.[@R37] Almost two-thirds of the studies (n=26, 53%) included a mix of clinicians, consumers and/or a range of others (eg, from industry, government and research backgrounds).[@R12] Of the priority-setting exercises published since 2011 (n=23), less than half (n=11, 48%) include a range of stakeholders.[@R11] Two studies compared research priorities of different stakeholders.[@R19] The majority of studies clearly explained the level of stakeholder involvement (n=28, 57%), and of those that included clinicians, 33% (n=14) selected specific individuals to panels or workshops.[@R15]

### Funding {#s3b5}

Most studies reported their funding source (n=31, 63%). Only two reported that no funding was received,[@R46] while the remainder received funding from either professional associations,[@R12] hospitals/institutes,[@R28] government,[@R20] consumer groups[@R22] or multiple sources.[@R11]

Themes of identified research priorities {#s3c}
----------------------------------------

Thirty-seven articles identified 294 research priorities that were presented as broad topics or statements such as 'biological perspective' or 'economic evaluations' to indicate a general research area that was considered a priority ([table 2](#T2){ref-type="table"} and online [supplementary appendix 4](#SP4){ref-type="supplementary-material"}). The median (IQR) number of broad topics identified per article was 7 (4--10). The most common theme they fell under was treatment (n=116, 39%), followed by patient/consumer perspectives (n=41, 14%). Few of these broad topics identified as research priorities were for economic evaluations (n=8, 3%),[@R17] or screening, diagnosis and assessment (n=3, 1%).[@R18] Thirteen of these broad topics were for specific foot conditions that required research and were not included in the thematic analysis because they could have been included in all themes.[@R47]
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###### 

Summary of broad (n=37 articles, 294 priorities) and specific (n=17 articles, 246 priorities) research priorities

  Category                                 Broad topics   Specific questions                         
  ---------------------------------------- -------------- -------------------- --- ------------ ---- ---
  Epidemiology and burden                  12 (4.1)       9                    5   6 (2.4)      2    2
  Aetiology and risk factors               19 (6.5)       13                   6   18 (7.3)     5    4
  Screening, diagnosis and assessment      3 (1.0)        3                    2   14 (5.7)     5    3
  Prevention                               5 (1.7)        5                    3   4 (1.6)      4    4
  Treatment                                116 (39.5)     25                   8   111 (45.1)   16   8
  Natural history, prognosis and outcome   22 (7.5)       11                   5   18 (7.3)     8    7
  Outcome measurement                      9 (3.1)        8                    4   18 (7.3)     5    3
  Economic evaluation                      8 (2.7)        8                    5   1 (0.4)      1    1
  Implementation                           6 (2.0)        5                    2   4 (1.6)      4    4
  Health services and systems              15 (5.1)       7                    5   9 (3.7)      4    3
  Research capacity building               28 (9.5)       9                    2   6 (2.4)      2    2
  Research methods                         11 (4.1)       8                    3   2 (0.8)      2    1
  Patient/consumer perspective             41 (13.9)      13                   5   21 (8.5)     5    2

Seventeen (38%) articles identified 246 priorities in the form of specific research questions ([table 2](#T2){ref-type="table"} and online [supplementary appendix 5](#SP5){ref-type="supplementary-material"}), with a median of 10 (IQR 5--17) priorities per article. Most of these specific research questions were for treatment (n=111, 45%) and only nine priorities (4%) from four priority-setting exercises were related to health services and systems research.[@R32] Most specific research questions identified as priorities were not reported in an actionable form. Only three (18%) articles reported all[@R31] or some[@R32] priorities in the form of Patient Intervention Control Outcomes (PICO)-formatted questions, and one article listed specific Cochrane review topics.[@R34]
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[Figures 2 and 3](#F2 F3){ref-type="fig"} show the number of broad research topics and specific research questions identified as priorities for each condition. The majority of both broad research topics and specific research questions identified as priorities were focused on treatments (n=116, 39% and n=111, 45%, respectively), although no treatment priorities were identified for SLE.[@R54] The majority of broad research topics listed as priorities (see [figure 2](#F2){ref-type="fig"}) were from priority-setting exercises that considered MSK conditions broadly, or across several conditions (n=170, 58%), with ≥2 priority topics listed for each theme. Despite only being considered in three priority-setting exercises,[@R22] the 24 broad research topics identified as priorities for osteoporosis were spread across nine themes. Only specific research questions were identified as priorities in priority-setting exercises for shoulder and orthopaedic surgery (see [figure 3](#F3){ref-type="fig"}). Specific research questions from two back pain priority-setting exercises[@R45] were identified as priorities across 11 research themes, while the one exercise for osteoporosis[@R40] only identified specific questions as priorities across the themes of prevention and treatment.

![Matrix of broad research topics identified as priorities in musculoskeletal (MSK) conditions. Size of the circles indicates the number (N) of priorities.](bmjopen-2018-023962f02){#F2}

![Matrix of specific research questions identified as priorities in musculoskeletal (MSK) conditions. Size of the circles indicates the number (N) of priorities.](bmjopen-2018-023962f03){#F3}

Discussion {#s4}
==========

We identified 49 articles published up until November 2017 that reported on some form of research prioritisation in MSK conditions. These initiatives identified 294 priorities listed as broad research topics and 246 priorities listed as specific research questions. Most priorities concerned treatment of MSK conditions broadly or multiple conditions. Relatively few articles considered implementation or health services and systems research, and only three priority-setting exercises translated some or all their priorities into specific, actionable well-constructed research questions (eg, in PICO format).

There is no universally accepted gold standard for priority-setting exercises, however, critical aspects include clearly defining the context, use of a detailed structured approach to guide the process, explicit criteria for what constitutes a priority, inclusiveness of all stakeholders and ensuring their representativeness, being well informed, transparency and plans for both implementation and evaluation.[@R64] The broad results of this study are similar to systematic reviews of priority-setting projects in other fields,[@R66] in that no study clearly considered all the critical aspects necessary to make a priority-setting exercise of maximum benefit. Many of the priority-setting exercises identified in this review involved a range of stakeholders. Engagement of all relevant stakeholders is recognised as an essential component of priority-setting exercises, since research that is relevant to all parties is more likely to be adopted in practice.[@R70] While nearly 50% of the priority-setting exercises in our review reported some level of consumer or patient engagement, similar to other systematic reviews,[@R70] the manner and extent of engagement varied.

As noted in other fields,[@R67] priority-setting exercises that only involved consumers, such as the one for SLE,[@R54] tended to list broader priorities relating to quality of life and support, consistent with systematic review evidence in this area.[@R72] In contrast, clinician-only priorities, such as those identified for orthopaedic surgery,[@R52] were generally more specific and focused on diagnostic or treatment aspects. Most also generally lacked sufficient methodological detail to enable replication including an explicit description of what would be considered a priority. Finally, only a minority were informed by a literature review, which while not relevant for all situations, is important in verifying that priorities are truly based on uncertainties or need.[@R9] While we did not note any improvement in priority-setting methods or stakeholder involvement in our review since publication of a checklist identifying the nine common themes of good priority-setting practice in 2010,[@R65] this may require more time. By contrast, systematic reviews of priority setting in other fields have noted an increased breadth of stakeholder involvement over time.[@R67] Such lack of detail severely limited the utility of the priorities identified as a starting point for ANZMUSC's own priority setting, and highlighted the need to be inclusive and comprehensive in conducting and reporting our own priority-setting exercises.

Disease burden is often a major consideration in identifying research priorities,[@R65] yet, the priorities that were identified in the 49 included articles do not reflect the relative burden of different MSK conditions. Back pain is the leading cause of disability globally,[@R73] but only three priority-setting exercises focused on generating priorities specifically for back pain. Similarly, neck pain is currently the sixth leading cause of global disability,[@R73] but it was not considered by any group. In contrast, osteoarthritis, which is currently the 12th leading cause of disability globally,[@R73] was considered in eight articles. A similar discord between burden and research was noted in a scoping review which found that in Australia, more clinical trials were being funded and conducted for osteoarthritis than back and neck pain combined.[@R5] The discord between burden of disease and condition-specific research prioritisation likely reflects a lack of recognition of disease burden and/or other drivers of priority setting.

It was also noteworthy that very few priority-setting exercises generated priorities related to economic evaluation, implementation and health services and systems, despite the ability for improvements in service delivery models to reduce the burden on the healthcare system and consequently improve patient care.[@R74] A distinct lack of priorities in health services and economic research relative to treatment and prevention priorities was also noted in a review of research priorities for kidney disease.[@R67] This may be the result of a lack of health service providers, funders and policy-makers involvement with priority-setting exercises.

It is difficult to assess the extent to which the priorities identified in these articles have informed current trials or research funding, or the extent to which they have been adopted into the health services field. Only a limited number of groups have reviewed their priority list, and none have performed a rigorous evaluation, therefore, the utility of these efforts is unknown. For example, while trials investigating self-management interventions and implementation trials were identified as research priorities by several groups, a scoping review looking at what types of MSK clinical trials had been funded by the Australian government from 2009 to 2013 found that most trials were focused on investigating the value of physical therapy and drug interventions.[@R5]

This systematic review has a number of strengths and limitations. The broad search strategy helped ensure that no conditions were excluded. Also independent screening, assessment and data extraction by two authors ensured that data were collected in a manner that minimised bias. Although we attempted to identify all relevant MSK condition priority-setting exercises, it is possible that some articles may have been missed, particularly those in the grey literature and in health policy documents. Further, the priority-setting exercises were all conducted in high-income countries and we did not identify any published priority-setting exercises specifically for low-income or middle-income countries. Therefore, the identified research priorities may or may not be transferable to these settings.

In summary, only 3 out of the 49 articles we reviewed identified specific research priorities in a well-constructed format using replicable methods, and most priorities focused on treatment. We recommend that future research priority-setting initiatives have a clear aim, use robust methods, include all relevant stakeholders and have a plan for implementation and evaluation. This will ensure greatest return on investment.
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